# Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

> **NCT01548807** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 19 (actual)

## Conditions studied

- Prostate Cancer Patients With Detectable PSA Following Prostatectomy

## Interventions

- **DRUG:** Everolimus (RAD001)

## Key facts

- **NCT ID:** NCT01548807
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2017-01-04
- **Final completion:** 2017-01-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01548807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01548807, "Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01548807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*